Health & Fitness
Health and Fitness
Health and Fitness 
Tue, October 12, 2010
Mon, October 11, 2010
Sun, October 10, 2010
Sat, October 9, 2010
Fri, October 8, 2010
Thu, October 7, 2010
Wed, October 6, 2010
Tue, October 5, 2010
Mon, October 4, 2010
Sun, October 3, 2010
Fri, October 1, 2010
Thu, September 30, 2010
Wed, September 29, 2010
Tue, September 28, 2010
Mon, September 27, 2010
Sun, September 26, 2010
Sat, September 25, 2010
Fri, September 24, 2010
Thu, September 23, 2010
Wed, September 22, 2010
Tue, September 21, 2010
Mon, September 20, 2010
Cubist Pharmaceuticals to Participate in Panel Discussion at Citia?s 5th Annual Biotech Day
LEXINGTON, Mass.--([ BUSINESS WIRE ])--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Robert Perez, Cubista� EVP and COO, will participate in a panel discussion on Tuesday, October 5, at 2 p.m. Eastern Time, at Citia�s 5th Annual Biotech Day being held at the Westin Waterfront Hotel in Boston. The panel will discuss the topic How to Kill Superbugs: Novel Antibiotics to Hit Drug Resistance Bacteria. (Live audio with slides webcast)
This panel discussion will be accessible live through Cubista�s website at [ www.cubist.com ] in the Investor Relations Conference Calendar section and will remain available there for a period of 30 days after the presentations.
About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN� (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides. The Cubist clinical product pipeline currently consists of a Phase 2 program focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms; and a Phase 2 program for the treatment of CDAD (Clostridium difficile-associated diarrhea). Cubist is also working on several pre-clinical programs being developed to address areas of significant medical needs. These include an anti-infective program for the treatment of respiratory syncytial virus (RSV) in children, therapies to treat various serious bacterial infections, and agents to treat acute pain. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubista�s web site at [ www.cubist.com ].
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.
